Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 14/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.38 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 2/20 | 0.33 |
| ▸ | ABL1 | P00519 | 2/20 | 0.33 |
| ▸ | EGFR | P00533 | 2/20 | 0.33 |
| ▸ | HCK | P08631 | 2/20 | 0.33 |
| ▸ | SRC | P12931 | 2/20 | 0.33 |
| ▸ | KDR | P35968 | 2/20 | 0.33 |
| ▸ | MTOR | P42345 | 2/20 | 0.33 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.33 |
| ▸ | PRKDC | P78527 | 2/20 | 0.33 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.33 |
| ▸ | ACHE | P22303 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1485662 | 0.82 | SRC (0.35) | PIK3CAPIK3CBPIK3CDPIK3CGNR3C2 | |
| SCHEMBL1431710 | 0.82 | KDM4E (0.36) | NR3C2 | |
| SCHEMBL30281175 | 0.82 | PIK3CA (0.32) | PIK3CAPIK3CBPIK3CDPIK3CGACHE | |
| SCHEMBL30281283 | 0.81 | ACHE (0.33) | PIK3CAPIK3CBPIK3CDPIK3CGACHE | |
| SCHEMBL28976852 | 0.81 | KDM4E (0.36) | NR3C2 | |
| SCHEMBL18018738 | 0.81 | DGAT1 (0.33) | PIK3CANR3C2 | |
| Lithium Ion SCHEMBL25376591 | 0.79 | DGAT1 (0.30) | — | |
| SCHEMBL11854415 | 0.79 | PARP10 (0.33) | PIK3CA | |
| SCHEMBL8950238 | 0.78 | KMT2A (0.31) | PIK3CAPIK3CDPIK3CG | |
| SCHEMBL8950240 | 0.78 | PIK3CA (0.38) | PIK3CANR3C2RETKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271951-A1 | DIFLUOROCYCLOHEXYL DERIVATIVES AS IL-17 MODULATORS | UCB BIOPHARMA SRL (SOCIETE A RESPONSABILITE LIMITEE) (BE) | 2023-08-31 | — | — | US | claimed |
| US-20230357168-A1 | CARBOBICYCLIC NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTION | UNIV HONG KONG CHINESE (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230357168-A1 | CARBOBICYCLIC NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTION | UNIV HONG KONG CHINESE (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230271951-A1 | DIFLUOROCYCLOHEXYL DERIVATIVES AS IL-17 MODULATORS | UCB BIOPHARMA SRL (SOCIETE A RESPONSABILITE LIMITEE) (BE) | 2023-08-31 | — | — | US | disclosed |
| CN-115867348-A | Imidazopyrimidines as IL-17 modulators | 詹森药业有限公司 | 2023-03-28 | — | — | CN | disclosed |
| EP-4143195-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | Janssen Pharmaceutica NV (BE) | 2023-03-08 | — | — | EP | disclosed |
| CN-115702024-A | Difluorocyclohexyl derivatives as IL-17 modulators | UCB生物制药有限责任公司 | 2023-02-14 | — | — | CN | disclosed |
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| US-20200031805-A1 | ARYL HYDROCARBON RECEPTOR (AHR) MODULATOR COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2020-01-30 | — | — | US | disclosed |
| US-20200031805-A1 | ARYL HYDROCARBON RECEPTOR (AHR) MODULATOR COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2020-01-30 | — | — | US | disclosed |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
| US-10000482-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2018-06-19 | — | — | US | disclosed |
| US-9637491-B2 | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-05-02 | — | — | US | disclosed |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
| WO-2014060113-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2014-04-24 | — | — | WO | disclosed |
| WO-2014060112-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2014-04-24 | — | — | WO | disclosed |
| US-20130289013-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | SUNOVION PHARMACEUTICALS INC. | 2013-10-31 | — | — | US | disclosed |
| US-8497278-B2 | Imidazo[1,2-a]pyridine compounds | SUNOVION PHARMACEUTICALS INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-20110166146-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | SUNOVION PHARMACEUTICALS INC. (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166146-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | PAICS, ITPA, DPYD | PIK3CA 637/4885PIK3CB 834/4885PIK3CD 1108/4885 |
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | PIK3CA 1016/4885PIK3CB 1106/4885PIK3CD 961/4885 |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | LRRK2, MYLK2, MYLK | PIK3CA 410/4885PIK3CB 621/4885PIK3CD 542/4885 |
| US-20230271951-A1 | DIFLUOROCYCLOHEXYL DERIVATIVES AS IL-17 MODULATORS | IL17A, IL2, IL23R | PIK3CA 3694/4885PIK3CB 1920/4885PIK3CD 1597/4885 |
| US-20130289013-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | PAICS, ITPA, DPYD | PIK3CA 637/4885PIK3CB 834/4885PIK3CD 1108/4885 |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | PIK3CA 1016/4885PIK3CB 1106/4885PIK3CD 961/4885 |
| US-20200031805-A1 | ARYL HYDROCARBON RECEPTOR (AHR) MODULATOR COMPOUNDS | AHR, ARNT, AIPL1 | PIK3CA 4108/4885PIK3CB 4464/4885PIK3CD 4603/4885 |
| US-20230357168-A1 | CARBOBICYCLIC NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTION | PNP, SLC29A1, SLC29A2 | PIK3CA 1774/4885PIK3CB 2161/4885PIK3CD 2488/4885 |
| US-10000482-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | PIK3CA 846/4885PIK3CB 912/4885PIK3CD 836/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | PIK3CA 846/4885PIK3CB 912/4885PIK3CD 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.